Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1352548 | 0.91 | DRD2 (0.45) | DRD2SIGMAR1TACR1ALDH1A1ALDH3A1 | |
| SCHEMBL24152329 | 0.85 | GSK3B (0.50) | DRD2SIGMAR1TACR1ALDH1A1CHRM2 | |
| SCHEMBL28980928 | 0.78 | DRD2 (0.43) | DRD2OPRL1TACR1ALDH1A1DRD4 | |
| SCHEMBL8555677 | 0.76 | DRD2 (0.61) | DRD2SIGMAR1OPRM1OPRK1OPRL1 | |
| SCHEMBL1349584 | 0.75 | DRD2 (0.54) | DRD2SIGMAR1OPRM1OPRK1OPRL1 | |
| SCHEMBL11447242 | 0.74 | ALDH1A1 (0.51) | DRD2OPRL1ALDH1A1DRD3DRD4 | |
| SCHEMBL11594479 | 0.72 | DRD2 (0.66) | DRD2SIGMAR1OPRM1OPRK1OPRL1 | |
| SCHEMBL30336993 | 0.71 | TP53 (0.45) | ALDH1A1MAPTHSD17B10 | |
| SCHEMBL30336973 | 0.71 | KMT2A (0.49) | SIGMAR1OPRM1OPRL1DRD4MEN1 | |
| SCHEMBL1351856 | 0.71 | DRD2 (0.55) | DRD2SIGMAR1OPRM1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160052929-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | ABBVIE INC. | 2016-02-25 | — | — | US | disclosed |
| US-9133206-B2 | Benzodiazepine and pyridodiazepine derivatives | ABBVIE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140163014-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| US-8673896-B2 | Benzodiazepine and pyridodiazepine derivatives | ABBVIE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20110288069-A1 | Benzodiazepine and Pyridodiazepine Derivatives | ABBOTT LABORATORIES (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288069-A1 | Benzodiazepine and Pyridodiazepine Derivatives | GABRA3, GABRB3, GABRA1 | DRD2 56/4885SIGMAR1 149/4885OPRM1 137/4885 |
| US-20160052929-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | GABRA3, GABRB3, GABRA1 | DRD2 56/4885SIGMAR1 149/4885OPRM1 137/4885 |
| US-20140163014-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | GABRA3, GABRB3, GABRA1 | DRD2 56/4885SIGMAR1 149/4885OPRM1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.